I have a slightly different understanding of Arm A, or maybe we're saying the same and I just misread. MultiTAA was applied after 3 months of chemo, which is the typical response period for chemo. Then when they applied MultiTAA and responses occurred.
Arm A: This arm was designed to evaluate the safety and potential efficacy of using MultiTAA cells as part of first-line treatment for patients with pancreatic cancer. These patients in the chemo-responsive arm have completed or will complete at least three months of standard-of-care chemotherapy (gemcitabine/nab-paclitaxel or FOLFIRINOX) – the period during which a response to chemotherapy would typically occur – before receiving up to six administrations of MultiTAA T cells in conjunction with chemotherapy.
Out of the 9 evaluable patients (one patient was too early to be evaluated):3 patients experienced objective responses after administration of MultiTAA cells1 patient experienced a complete response2 patients experienced partial responses4 patients experienced stable disease; 2 patients within stable disease boundaries (+20%/-30%) saw reversal of tumor growth – tumors previously growing after chemotherapy alone showed shrinkage after administration of MultiTAA cells1 patient experienced a mixed response (some lesions increased in size and others decreased for a net zero change in size of tumor lesions)1 patient experienced disease progressionOverall tumor volume shrinkage was observed in six out of the eight patients with a measurable tumor after administration of MultiTAA cells. One evaluable patient did not have tumor measurements for analysis.Of the 9 evaluable patients, over half have survived to or beyond the historical median overall survival associated with their respective chemotherapy regimens, and 7 of the 9 patients remain alive.In patients responding to therapy, significant expansion of the infused MultiTAA cells was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens.
